Visiting Scientist

Research Group Home Page: 

Work address: 
Cancer Research UK Cambridge Institute University of Cambridge Li Ka Shing Centre Robinson Way Cambridge CB2 0RE
Publications: 

POSEIDON phase 1b results: safety, efficacy and ctDNA response of taselisib combined with tamoxifen in hormone receptor positive metastatic breast cancer patients.

E-pub date: 31 Jul 2019


Utilization of volumetric magnetic resonance imaging for baseline and surveillance imaging in Neuro-oncology.

E-pub date: 28 Feb 2019


Next Generation-Targeted Amplicon Sequencing (NG-TAS): an optimised protocol and computational pipeline for cost-effective profiling of circulating tumour DNA.

E-pub date: 31 Dec 2018


An extended phase Ib study of epertinib, an orally active reversible dual EGFR/HER2 tyrosine kinase inhibitor, in patients with solid tumours.

E-pub date: 01 Nov 2018


Enhanced detection of circulating tumor DNA by fragment size analysis.

E-pub date: 31 Oct 2018


Clinical Development of Novel Drug-Radiotherapy Combinations.

E-pub date: 31 Oct 2018


Circulating biomarkers and resistance to endocrine therapy in metastatic breast cancers: correlative results from AZD9496 oral SERD Phase I trial.

E-pub date: 31 Jul 2018


A First-in-Human Study of the New Oral Selective Estrogen Receptor Degrader AZD9496 for ER+/HER2- Advanced Breast Cancer.

E-pub date: 13 Feb 2018


The potential consequences for cancer care and cancer research of Brexit.

E-pub date: 31 Aug 2017


Liquid biopsies come of age: towards implementation of circulating tumour DNA.

E-pub date: 01 Apr 2017


A phase I pharmacokinetic and safety study of cabazitaxel in adult cancer patients with normal and impaired renal function.

E-pub date: 31 Dec 2016


Clinical development of new drug-radiotherapy combinations.

E-pub date: 31 Oct 2016


A Biobank of Breast Cancer Explants with Preserved Intra-tumor Heterogeneity to Screen Anticancer Compounds.

E-pub date: 22 Sep 2016


An Association of Cancer Physicians’ strategy for improving services and outcomes for cancer patients.

E-pub date: 31 Aug 2016


Plasma Metabolomic Changes following PI3K Inhibition as Pharmacodynamic Biomarkers: Preclinical Discovery to Phase I Trial Evaluation.

E-pub date: 01 Jun 2016


Understanding Oestrogen Receptor Function in Breast Cancer and its Interaction with the Progesterone Receptor. New Preclinical Findings and their Clinical Implications.

E-pub date: 31 Jan 2016


A Bayesian adaptive design for biomarker trials with linked treatments.

E-pub date: 01 Sep 2015


Antitumor activity in RAS-driven tumors by blocking AKT and MEK.

E-pub date: 15 Feb 2015


Phase 1 dose-escalation study of S-222611, an oral reversible dual tyrosine kinase inhibitor of EGFR and HER2, in patients with solid tumours.

E-pub date: 31 Jan 2015


First-in-human phase I study of pictilisib (GDC-0941), a potent pan-class I phosphatidylinositol-3-kinase (PI3K) inhibitor, in patients with advanced solid tumors.

E-pub date: 01 Jan 2015


Interrogating two schedules of the AKT inhibitor MK-2206 in patients with advanced solid tumors incorporating novel pharmacodynamic and functional imaging biomarkers.

E-pub date: 15 Nov 2014


The poly(ADP-ribose) polymerase inhibitor niraparib (MK4827) in BRCA mutation carriers and patients with sporadic cancer: a phase 1 dose-escalation trial.

E-pub date: 31 Aug 2013


A phase I study of quisinostat (JNJ-26481585), an oral hydroxamate histone deacetylase inhibitor with evidence of target modulation and antitumor activity, in patients with advanced solid tumors.

E-pub date: 01 Aug 2013


Genetic heterogeneity in breast cancer: the road to personalized medicine?

E-pub date: 18 Jun 2013


First-in-man clinical trial of the oral pan-AKT inhibitor MK-2206 in patients with advanced solid tumors.

E-pub date: 10 Dec 2011


Baseline circulating tumor cell counts significantly enhance a prognostic score for patients participating in phase I oncology trials.

E-pub date: 01 Aug 2011


Toxicity associated with capecitabine plus oxaliplatin in colorectal cancer before and after an institutional policy of capecitabine dose reduction.

E-pub date: 04 Jan 2011


Weekly paclitaxel in the treatment of recurrent ovarian cancer.

E-pub date: 31 Oct 2010


Phase I safety, pharmacokinetic, and pharmacogenomic trial of ES-285, a novel marine cytotoxic agent, administered to adult patients with advanced solid tumors.

E-pub date: 01 Jun 2009


Thalidomide is highly effective in a patient with meningeal acute myeloid leukaemia.

E-pub date: 01 Jan 2004


Drug resistance reversal–are we getting closer?

E-pub date: 01 Nov 2003


Spontaneous remission of low-grade B-cell non-Hodgkin’s lymphoma following withdrawal of methotrexate in a patient with rheumatoid arthritis: case report and review of the literature.

E-pub date: 31 Aug 2002


Carcinoma-induced diffuse pulmonary haemorrhage.

E-pub date: 01 Mar 2002


Show all